These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

785 related articles for article (PubMed ID: 33249201)

  • 1. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
    Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
    Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
    Raue F; Frank-Raue K
    Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Patrizio A; Paparo SR; Marone G; Galdiero MR; Guglielmi G; Foddis R; Cristaudo A; Antonelli A
    Semin Cancer Biol; 2022 Feb; 79():203-216. PubMed ID: 32569821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Targeted Therapies of Aggressive Thyroid Cancer.
    Ferrari SM; Fallahi P; Politti U; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A
    Front Endocrinol (Lausanne); 2015; 6():176. PubMed ID: 26635725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes and risk stratification for papillary thyroid carcinoma presenting with distant metastasis before the era of tyrosine kinase inhibitors.
    Matsuzu K; Sugino K; Masudo K; Mori K; Ono R; Yamazaki H; Masaki C; Akaishi J; Kiyomi Yamada H; Tomoda C; Suzuki A; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Takami H; Ito K
    Endocr J; 2020 Aug; 67(8):869-876. PubMed ID: 32350192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
    Filetti S; Durante C; Hartl D; Leboulleux S; Locati LD; Newbold K; Papotti MG; Berruti A;
    Ann Oncol; 2019 Dec; 30(12):1856-1883. PubMed ID: 31549998
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
    Zhang L; Feng Q; Wang J; Tan Z; Li Q; Ge M
    Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188928. PubMed ID: 37257629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
    van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
    Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
    Capdevila J; Krajewska J; Hernando J; Robinson B; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Williamson D; Levytskyy R; Oliver J; Keam B; Brose MS
    Thyroid; 2024 Mar; 34(3):347-359. PubMed ID: 38062732
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeted Therapy in Thyroid Cancer: State of the Art.
    Valerio L; Pieruzzi L; Giani C; Agate L; Bottici V; Lorusso L; Cappagli V; Puleo L; Matrone A; Viola D; Romei C; Ciampi R; Molinaro E; Elisei R
    Clin Oncol (R Coll Radiol); 2017 May; 29(5):316-324. PubMed ID: 28318881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
    Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
    J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Survival After Multimodal Approach with
    Wu D; Gomes Lima CJ; Moreau SL; Kulkarni K; Zeymo A; Burman KD; Wartofsky L; Van Nostrand D
    Thyroid; 2019 Jul; 29(7):971-978. PubMed ID: 31017051
    [No Abstract]   [Full Text] [Related]  

  • 16. Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects.
    Puliafito I; Esposito F; Prestifilippo A; Marchisotta S; Sciacca D; Vitale MP; Giuffrida D
    Front Endocrinol (Lausanne); 2022; 13():860671. PubMed ID: 35872981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiated Thyroid Carcinoma Long-Term Prognostic Factors.
    Luis PO; Lucía MA; Hugo RC; Ramiro RM; Stalin CQ
    Int J Surg Oncol; 2024; 2024():1067447. PubMed ID: 39291250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer.
    Ferrari SM; Elia G; Ragusa F; Paparo SR; Mazzi V; Miccoli M; Galdiero MR; Varricchi G; Foddis R; Guglielmi G; Spinelli C; La Motta C; Benvenga S; Antonelli A; Fallahi P
    Expert Opin Investig Drugs; 2021 Sep; 30(9):913-921. PubMed ID: 34428101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Poorly Differentiated Thyroid Cancer and Differentiated High-Grade Thyroid Carcinoma.
    Alam IS; Patel KN
    Surg Clin North Am; 2024 Aug; 104(4):751-765. PubMed ID: 38944496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up.
    Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H
    Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 40.